• 業務咨詢

  中國：

  Email: marketing@www.msjidi.com

  業務咨詢專線：400-780-8018

  （僅限服務咨詢，其他事宜請撥打川沙總部電話）

  川沙總部電話: +86 (21) 5859-1500

  海外：

  +1(781)535-1428(U.S.)

  0044 7790 816 954 (Europe)

  Email:marketing@medicilon.com

Current pain management is largely limited to opioids and non-steroidal anti-inflammatory drugs. Developing new analgesic drugs remains important to address the unmet medical needs of chronic pain patients. Calcium-activated chloride channel anoctamin-1 (ANO1) is a potential analgesic target. DFBTA is a potent inhibitor with the IC₅₀ of 24 nM. DFBTA shows very weak cytotoxicity, cardiotoxicity, and acute toxicity, as well as excellent pharmacokinetics properties with oral bioavailability >75% and little brain penetration (<1.5% brain/plasma). In vivo PK were tested by Medicilon. 

Reference:

Yuxi Wang, et al. Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain. Eur J Med Chem. 2022 Jul 5;237:114413. doi: 10.1016/j.ejmech.2022.114413.